Danaher (DHR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.11
- Estimate
- $1.92
- Surprise
- +10.0%
- Revenue (period 2026-09-25)
- $6.55B
- Score at report (before → after)
- 6.0 → 6.0/10
Revenue source: xbrl.
How the report landed
Danaher (DHR) beat the $1.92 estimate with adjusted EPS of $2.11 — a large 10.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Hold at 6.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DHR Hold at 6.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +10.0% surprise compares with a +5.9% four-quarter average. Next scheduled report: 2027-01-27.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (2.8% away)
- Target reached (-0.9% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $236.11
- Stop
- $222.17
The stock trades at 39.1× trailing but 25.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.
DHR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $166.11B
- P/E (fwd)
- 25.3
- P/E (ttm)
- 39.1
- 52-week range
- $160.93–$242.80
- Off 52-week high
- 2.8%
- RSI (14)
- 52
- Volume vs avg
- 0.79×
- Score today
- 6.0/10